Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00137826
Status:
COMPLETED
Last Update Posted:
2011-12-26
First Post:
2005-08-29
Brief Title:
Bevacizumab Avastin and Erlotinib Tarceva in Previously Treated Mesothelioma
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Study Overview
Official Title:
Phase II Study of Bevacizumab Avastin and Erlotinib Tarceva in Previously Treated Malignant Mesothelioma
Status:
COMPLETED
Status Verified Date:
2011-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether the combination of the investigational drugs Avastin and Tarceva are effective in patients with mesothelioma who have previously been treated with chemotherapy
Detailed Description:
Each cycle of study treatment lasts 21 days The patient will take erlotinib by mouth once daily On day 1 of every cycle the patient will receive bevacizumab intravenously over a 30-90 minute time period
CT scans MRIs andor x-rays of the cancer site will be performed every 6 weeks 2 cycles to assess the extent of the response to treatment
Bloodwork will be performed before the first dose of erlotinib and bevacizumab at Cycle 1 Cycle 2 Cycle 3 and at the end of treatment
At the completion of the treatment a physical exam vital signs blood tests urine tests and standard radiologic testing will be performed
The duration of study depends upon how the patients mesothelioma responds to treatment as well as how well the patient tolerates the medication
CT scans MRIs andor x-rays of the cancer site will be performed every 6 weeks 2 cycles to assess the extent of the response to treatment
Bloodwork will be performed before the first dose of erlotinib and bevacizumab at Cycle 1 Cycle 2 Cycle 3 and at the end of treatment
At the completion of the treatment a physical exam vital signs blood tests urine tests and standard radiologic testing will be performed
The duration of study depends upon how the patients mesothelioma responds to treatment as well as how well the patient tolerates the medication
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None